정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 443 | Recruiting | Study of Gam-COVID-Vac in Adolescents | Vaccine Preventable Disease | Biological: Gam-COVID-vac M Biological: Placebo |
Phase 3 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, Moscow Healthcare Department | OTHER | 3000 | All | 12 Years ~ 17 Years | Children's City Clinical Hospital named after Z.A. Bashlyaeva of the Moscow Department of Health, Moscow, Russian Federation Morozovskaya Children's City Clinical Hospital of the Moscow Department of Health, Moscow, Russian Federation |
| 442 | Active, not recruiting | Study of GRAd-COV2 for the Prevention of COVID-19 in Adults | Covid19 | Biological: GRAd-COV2 Other: Placebo |
Phase 3 | ReiThera Srl, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani | INDUSTRY | 10300 | All | 18 Years | Ospedale Vittorio Emanuele Ii, Bisceglie, Barletta- Andria-Trani, Italy Istituto per le Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, RM, Italy Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy A.O. Sant'Anna E San Sebastiano Caserta, Caserta, Italy Asst Di Cremona, Cremona, Italy Azienda Ospedaliero-Universitaria Di Ferrara, Ferrara, Italy Ao Ospedali Riuniti - Foggia, Foggia, Italy E.O. Ospedali Galliera, Genova, Italy Presidio Ospedaliero Nord-Ospedale Santa Maria Goretti Latina, Latina, Italy Fondaz.Irccs Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy Asst Fatebenefratelli Sacco, Milano, Italy Ospedale S.Gerardo - Monza, Monza, Italy Azienda Ospedaliera Dei Colli - P Cotugno, Napoli, Italy Azienda Ospedaliera Universitaria Della Universita' Vanvitelli I Di Napoli, Napoli, Italy Az.Osp.Univ.P.Giaccone, Palermo, Italy Azienda Ospedaliero-Universitaria Di Parma, Parma, Italy Policlinico S. Matteo - Pavia, Pavia, Italy Azienda Usl Di Piacenza, Piacenza, Italy Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy Azienda Ospedaliera Policlinico Umberto I, Roma, Italy Policlinico A. Gemelli E C.I.C.- Policlinico Universitario A. Gemelli, Roma, Italy Ospedale Amedeo Di Savoia, Torino, Italy Azienda Sanitaria Universitaria Integrata Di Trieste, Trieste, Italy Asst Dei Sette Laghi, Varese, Italy Ospedale Unico Del Vercellese - Ospedale Sant'Andrea, Vercelli, Italy Centro Ricerche Cliniche Di Verona Srl, Verona, Italy |
| 441 | Completed | Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) | Confusion | Drug: Hesperidin Drug: Placebo |
Phase 2 | Montreal Heart Institute, Ingenew Pharmaceuticals Inc. | OTHER | 216 | All | 18 Years | Montreal Heart Institute, Montreal, Quebec, Canada |
| 440 | Not yet recruiting | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 | COVID-19 | Biological: UC-MSCs Drug: Placebo |
Not Applicable | Wuhan Union Hospital, China, Wuhan Hamilton Bio-technology Co., Ltd, China. | OTHER | 48 | All | 18 Years ~ 65 Years | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |
| 439 | Suspended | Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO | SARS-CoV-2 Infection | Drug: Sarilumab Drug: Azithromycin Drug: Hydroxychloroquine |
Phase 3 | Assistance Publique - Hopitaux de Paris | OTHER | 27 | All | 18 Years ~ 80 Years | AP-HP Hopital Avicenne, Bobigny, France AP-HP Hopital Ambroise Pare, Boulogne-Billancourt, France AP-HP Hopital Beaujon, Clichy, France AP-HP Hopital Pitie Salpetriere, Paris, France AP-HP Hopital Saint Antoine, Paris, France |
| 438 | Terminated | Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 | Coronavirus Infections | Drug: Naltrexone Drug: Ketamine Other: Placebo |
Phase 2 | William Beaumont Hospitals | OTHER | 70 | All | 18 Years | William Beaumont Hospital, Royal Oak, Michigan, United States |
| 437 | Not yet recruiting | Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19) | COVID-19 | Biological: SARS-CoV-2 Vaccine (Vero Cells), Inactivated Biological: Placebo |
Phase 2 | Shenzhen Kangtai Biological Products Co., LTD, Beijing Minhai Biotechnology Co., Ltd, Hunan Province Centers for Disease Control and Prevention | INDUSTRY | 480 | All | 3 Years ~ 17 Years | Hunan Provincial Center for Diseases Control and Prevention, Changsha, Hunan, China |